litlas
Log inCreate account

Margaret A. Shipp

Active 1986–2025

116
Papers
43,273
Citations
89
h-index
114
i10-index

Citations

Citations per year for Margaret A. Shipp1970: 1 citations1973: 1 citations1986: 2 citations1987: 3 citations1988: 4 citations1989: 11 citations1990: 12 citations1991: 17 citations1992: 11 citations1993: 20 citations1994: 19 citations1995: 24 citations1996: 17 citations1997: 52 citations1998: 46 citations1999: 46 citations2000: 58 citations2001: 76 citations2002: 120 citations2003: 163 citations2004: 186 citations2005: 210 citations2006: 222 citations2007: 235 citations2008: 251 citations2009: 229 citations2010: 238 citations2011: 250 citations2012: 281 citations2013: 297 citations2014: 349 citations2015: 562 citations2016: 557 citations2017: 669 citations2018: 641 citations2019: 1,791 citations2020: 1,845 citations2021: 1,732 citations2022: 1,080 citations2023: 823 citations2024: 1,240 citations2025: 490 citations2026: 6 citations1971–1972: no citations, so these years are not shown1974–1985: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,627 citing papers, 27.8% of this breakdownChina: 1,705 citing papers, 10.2% of this breakdownGermany: 1,027 citing papers, 6.2% of this breakdownFrance: 908 citing papers, 5.4% of this breakdownUnited Kingdom: 893 citing papers, 5.4% of this breakdownItaly: 868 citing papers, 5.2% of this breakdownCanada: 616 citing papers, 3.7% of this breakdownJapan: 573 citing papers, 3.4% of this breakdownSpain: 557 citing papers, 3.3% of this breakdownSwitzerland: 475 citing papers, 2.9% of this breakdownNetherlands: 387 citing papers, 2.3% of this breakdownAustralia: 374 citing papers, 2.2% of this breakdown
0%27.8%Other 22%

Institutions

Fields

  • Medicine64.2%
  • Biochemistry, Genetics and Molecular Biology23.6%
  • Immunology and Microbiology8.2%
  • Computer Science2.1%
  • Neuroscience0.4%
  • Engineering0.3%
  • Other1.2%

Topics

  • Lymphoma Diagnosis and Treatment12.7%
  • Cancer Immunotherapy and Biomarkers6.2%
  • CAR-T cell therapy research4.9%
  • Immune Cell Function and Interaction4.4%
  • Chronic Lymphocytic Leukemia Research3.8%
  • Viral-associated cancers and disorders3.5%
  • Other64.5%

Coauthors

All papers

Open in search
  1. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

    Authors: Elı́as Campo, Elaine S. Jaffe, James R. Cook, Leticia Quintanilla‐Martínez, Steven H. Swerdlow, Kenneth C. Anderson, Pierre Brousset, Lorenzo Cerroni, Laurence de Leval, Stefan Dirnhofer, Ahmet Doǧan, Andrew L. Feldman, Falko Fend, Jonathan W. Friedberg, Philippe Gaulard, Paolo Ghia, Steven M. Horwitz, Rebecca L. King, Gilles Salles, Jesús F. San Miguel, John F. Seymour, Steven P. Treon, Julie M. Vose, Emanuele Zucca, Ranjana H. Advani, Stephen M. Ansell, Wing-Yan Au, Carlos Barrionuevo, Leif Bergsagel, Wing C. Chan, Jeffrey I. Cohen, Francesco d’Amore, Andrew Davies, Brunangelo Falini, Irene M. Ghobrial, John R. Goodlad, John G. Gribben, Eric D. Hsi, Brad S. Kahl, Won-Seog Kim, Shaji Kumar, Ann S. LaCasce, Camille Laurent, Georg Lenz, John P. Leonard, Michael P. Link, Armando López‐Guillermo, María‐Victoria Mateos, Elizabeth Macintyre, Ari Melnick, Franck Morschhauser, Shigeo Nakamura, Marina Narbaitz, Astrid Pavlovsky, Stefano Pileri, Miguel Á. Piris, Barbara Pro, S. Vincent Rajkumar, Steven T. Rosen, Birgitta Sander, Laurie H. Sehn, Margaret A. Shipp, Sonali M. Smith, Louis M. Staudt, Catherine Thieblemont, Thomas Tousseyn, Wyndham H. Wilson, Tadashi Yoshino, Pier Luigi Zinzani, Martin Dreyling, David W. Scott, Jane N. Winter, Andrew D. Zelenetz - Blood 2022 cited by 1,506

  2. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes

    Authors: Bjoern Chapuy, Chip Stewart, Andrew Dunford, Jaegil Kim, Atanas Kamburov, Robert Redd, Mike S. Lawrence, Margaretha G.M. Roemer, Amy J. Li, Marita Ziepert, Annette M. Staiger, Jeremiah A. Wala, Matthew D. Ducar, Ignaty Leshchiner, Ester Rheinbay, Amaro Taylor‐Weiner, Caroline A. Coughlin, Julian M. Hess, Chandra Sekhar Pedamallu, Dimitri Livitz, Daniel Rosebrock, Mara Rosenberg, Adam Tracy, Heike Horn, Paul Van Hummelen, Andrew L. Feldman, Brian K. Link, Anne J. Novak, James R. Cerhan, Thomas M. Habermann, Reiner Siebert, Andreas Rosenwald, Aaron R. Thorner, Matthew Meyerson, Todd R. Golub, Rameen Beroukhim, Gerald Wulf, German Ott, Scott J. Rodig, Stefano Monti, Donna Neuberg, Markus Loeffler, Michael Pfreundschuh, Lorenz Trümper, Gad Getz, Margaret A. Shipp - Nature Medicine 2018 cited by 1,972

  3. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

    Authors: Stephen M. Ansell, Alexander M. Lesokhin, Ivan Borrello, Ahmad Halwani, Emma C. Scott, Martin Gutierrez, Stephen J. Schuster, Michael Millenson, Deepika Cattry, Gordon J. Freeman, Scott J. Rodig, Bjoern Chapuy, Azra H. Ligon, Lili Zhu, Joseph F. Grosso, Su Young Kim, John M. Timmerman, Margaret A. Shipp, Philippe Armand - New England Journal of Medicine 2014 cited by 3,547

  4. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning

    Authors: Margaret A. Shipp, Ken N. Ross, Pablo Tamayo, Andrew P. Weng, Jeffery L. Kutok, Ricardo C.T. Aguiar, Michelle Gaasenbeek, Michael Angelo, Michael Reich, Geraldine S. Pinkus, Tane S. Ray, Margaret A. Koval, Kim Last, A. J. Norton, T. Andrew Lister, Jill P. Mesirov, Donna Neuberg, Eric S. Lander, Jon C. Aster, Todd R. Golub - Nature Medicine 2002 cited by 2,450

  5. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome

    Authors: Margaretha G.M. Roemer, Ranjana H. Advani, Azra H. Ligon, Yasodha Natkunam, Robert Redd, Heather Homer, Courtney Connelly, Heather H. Sun, Sarah E. Daadi, Gordon J. Freeman, Philippe Armand, Bjoern Chapuy, Daphne de Jong, Richard T. Hoppe, Donna Neuberg, Scott J. Rodig, Margaret A. Shipp - Journal of Clinical Oncology 2016 cited by 803

  6. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma

    Authors: Michael R. Green, Stefano Monti, Scott J. Rodig, Przemysław Juszczyński, Treeve Currie, Evan A. O’Donnell, Bjoern Chapuy, Kunihiko Takeyama, Donna Neuberg, Todd R. Golub, Jeffery L. Kutok, Margaret A. Shipp - Blood 2010 cited by 1,297

  7. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial

    Authors: Philippe Armand, Andreas Engert, Anas Younes, Michelle A. Fanale, Armando Santoro, Pier Luigi Zinzani, John M. Timmerman, Graham P. Collins, Radhakrishnan Ramchandren, Jonathon B. Cohen, Jan Paul de Boer, John Kuruvilla, Kerry J. Savage, Marek Trněný, Margaret A. Shipp, Kazunobu Kato, Anne Sumbul, Benedetto Farsaci, Stephen M. Ansell - Journal of Clinical Oncology 2018 cited by 754

  8. Metabolic Signatures Uncover Distinct Targets in Molecular Subsets of Diffuse Large B Cell Lymphoma

    Authors: Pilar Caro, Amar U. Kishan, Erik Norberg, Illana A. Stanley, Bjoern Chapuy, Scott B. Ficarro, Klaudia Polak, Daniel Tondera, John Gounarides, Hong Yin, Feng Zhou, Michael R. Green, Lin‐Feng Chen, Stefano Monti, Jarrod A. Marto, Margaret A. Shipp, Nika N. Danial - Cancer Cell 2012 cited by 528

  9. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

    Authors: Alexander M. Lesokhin, Stephen M. Ansell, Philippe Armand, Emma Scott, Ahmad Halwani, Martin Gutierrez, Michael Millenson, Adam D. Cohen, Stephen J. Schuster, Daniel Lebovic, Madhav V. Dhodapkar, David Avigan, Bjoern Chapuy, Azra H. Ligon, Gordon J. Freeman, Scott J. Rodig, Deepika Cattry, Lili Zhu, Joseph F. Grosso, M. Brigid Garelik, Margaret A. Shipp, Ivan Borrello, John M. Timmerman - Journal of Clinical Oncology 2016 cited by 1,011

  10. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

    Authors: Robert Chen, Pier Luigi Zinzani, Michelle A. Fanale, Philippe Armand, Nathalie A. Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A. Shipp, Yinghua Zhang, Alejandro D. Ricart, Arun Balakumaran, Craig H. Moskowitz, for the KEYNOTE-087 - Journal of Clinical Oncology 2017 cited by 985

  11. PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies

    Authors: Benjamin J. Chen, Bjoern Chapuy, Jing Ouyang, Heather H. Sun, Margaretha G.M. Roemer, Mina L. Xu, Hongbo Yu, Christopher D.�M. Fletcher, Gordon J. Freeman, Margaret A. Shipp, Scott J. Rodig - Clinical Cancer Research 2013 cited by 839

  12. Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma

    Authors: Bjoern Chapuy, Michael R. McKeown, Charles Y. Lin, Stefano Monti, Margaretha G.M. Roemer, Jun Qi, Peter B. Rahl, Heather H. Sun, Kelly T. Yeda, John G. Doench, Elaine C. Reichert, Andrew L. Kung, Scott J. Rodig, Richard A. Young, Margaret A. Shipp, James E. Bradner - Cancer Cell 2013 cited by 766

  13. Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy

    Authors: Michael R. Green, Scott J. Rodig, Przemysław Juszczyński, Jing Ouyang, Papiya Sinha, Evan A. O’Donnell, Donna Neuberg, Margaret A. Shipp - Clinical Cancer Research 2012 cited by 683

  14. Targetable genetic features of primary testicular and primary central nervous system lymphomas

    Authors: Bjoern Chapuy, Margaretha G.M. Roemer, Chip Stewart, Yuxiang Tan, Ryan Abo, Liye Zhang, Andrew Dunford, David M. Meredith, Aaron R. Thorner, Ekaterina S. Jordanova, Gang Liu, Friedrich Feuerhake, Matthew D. Ducar, Gerald Illerhaus, Daniel Gusenleitner, Erica Linden, Heather H. Sun, Heather Homer, Miyuki Aono, Geraldine S. Pinkus, Azra H. Ligon, Keith L. Ligon, Judith A. Ferry, Gordon J. Freeman, Paul Van Hummelen, Todd R. Golub, Gad Getz, Scott J. Rodig, Daphne de Jong, Stefano Monti, Margaret A. Shipp - Blood 2015 cited by 599

  15. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma

    Authors: Margaretha G.M. Roemer, Robert Redd, Fathima Zumla Cader, Christine J. Pak, Sara Abdelrahman, Jing Ouyang, Stephanie Sasse, Anas Younes, Michelle A. Fanale, Armando Santoro, Pier Luigi Zinzani, John M. Timmerman, Graham P. Collins, Radhakrishnan Ramchandren, Jonathon B. Cohen, Jan Paul de Boer, John Kuruvilla, Kerry J. Savage, Marek Trněný, Stephen M. Ansell, Kazunobu Kato, Benedetto Farsaci, Anne Sumbul, Philippe Armand, Donna Neuberg, Geraldine S. Pinkus, Azra H. Ligon, Scott J. Rodig, Margaret A. Shipp - Journal of Clinical Oncology 2018 cited by 367

  16. NLRC5/MHC class I transactivator is a target for immune evasion in cancer

    Authors: Sayuri Yoshihama, Jason Roszik, Isaac Downs, Torsten Meißner, Saptha Vijayan, Bjoern Chapuy, Tabasum Sidiq, Margaret A. Shipp, Gregory Lizée, Koichi S. Kobayashi - National Academy of Sciences, Proceedings of the National Academy of Sciences 2016 cited by 270

  17. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma

    Authors: Lakshmi Nayak, Fábio M. Iwamoto, Ann S. LaCasce, Srinivasan Mukundan, Margaretha G.M. Roemer, Bjoern Chapuy, Philippe Armand, Scott J. Rodig, Margaret A. Shipp - Blood 2017 cited by 459

  18. Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study

    Authors: Stephen M. Ansell, Monique C. Minnema, Peter Johnson, John M. Timmerman, Philippe Armand, Margaret A. Shipp, Scott J. Rodig, Azra H. Ligon, Margaretha G.M. Roemer, Nishitha Reddy, Jonathon B. Cohen, Sarit Assouline, Michelle Poon, Manish Sharma, Kazunobu Kato, Selda Samakoglu, Anne Sumbul, Andrew Grigg - Journal of Clinical Oncology 2019 cited by 363

  19. Glycosylation-Dependent Lectin-Receptor Interactions Preserve Angiogenesis in Anti-VEGF Refractory Tumors

    Authors: Diego O. Croci, Juan P. Cerliani, Tomás Dalotto‐Moreno, Santiago P. Méndez‐Huergo, Iván Mascanfroni, Sebastián Dergan‐Dylon, Marta A. Toscano, Julio J. Caramelo, Juan J. García‐Vallejo, Jing Ouyang, Enrique A. Mesri, Melissa R. Junttila, Carlos Bais, Margaret A. Shipp, Mariana Salatino, Gabriel A. Rabinovich - Cell 2014 cited by 507

  20. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing

    Authors: Jens G. Lohr, Petar Stojanov, Michael S. Lawrence, Daniel Auclair, Bjoern Chapuy, Carrie Sougnez, Peter Cruz‐Gordillo, Birgit Knoechel, Yan W. Asmann, Susan L. Slager, Anne J. Novak, Ahmet Doǧan, Stephen M. Ansell, Brian K. Link, Lihua Zou, Joshua Gould, Gordon Saksena, Nicolas Stransky, Claudia Rangel‐Escareño, Juan Carlos Fernández-López, Alfredo Hidalgo‐Miranda, Jorge Meléndez-Zajgla, Enrique Hernández–Lemus, Angela Schwarz‐Cruz y Celis, Iván Imaz-Rosshandler, Akinyemi I. Ojesina, Joonil Jung, Chandra Sekhar Pedamallu, Eric S. Lander, Thomas M. Habermann, James R. Cerhan, Margaret A. Shipp, Gad Getz, Todd R. Golub - National Academy of Sciences, Proceedings of the National Academy of Sciences 2012 cited by 980

  21. Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma

    Authors: Christopher D. Carey, Daniel Gusenleitner, Mikel Lipschitz, Margaretha G.M. Roemer, Edward C. Stack, Evisa Gjini, Xihao Hu, Robert Redd, Gordon J. Freeman, Donna Neuberg, F. Stephen Hodi, Xiaole Shirley Liu, Margaret A. Shipp, Scott J. Rodig - Blood 2017 cited by 332

  22. Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas

    Authors: Bruce D. Cheson, Sandra J. Horning, B Coiffier, Margaret A. Shipp, Richard I. Fisher, Joseph M. Connors, Tim Lister, Julie M. Vose, Antonio J Grillo-López, Anton Hagenbeek, Fernando Cabanillas, Donald Klippensten, Wolfgang Hiddemann, Ronald A. Castellino, Nancy L. Harris, Jamés O. Armitage, William Carter, Richard T. Hoppe, George P. Canellos - Journal of Clinical Oncology 1999 cited by 3,490

  23. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

    Authors: Anas Younes, Armando Santoro, Margaret A. Shipp, Pier Luigi Zinzani, John M. Timmerman, Stephen M. Ansell, Philippe Armand, Michelle A. Fanale, Voravit Ratanatharathorn, John Kuruvilla, Jonathon B. Cohen, Graham P. Collins, Kerry J. Savage, Marek Trněný, Kazunobu Kato, Benedetto Farsaci, Susan Parker, Scott J. Rodig, Margaretha G.M. Roemer, Azra H. Ligon, Andreas Engert - The Lancet Oncology 2016 cited by 924

  24. Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study

    Authors: Radhakrishnan Ramchandren, Eva Domingo‐Doménech, Antonio Rueda, Marek Trněný, Tatyana Feldman, Hun Ju Lee, Mariano Provencio, Christian Sillaber, Jonathon B. Cohen, Kerry J. Savage, Wolfgang Willenbacher, Azra H. Ligon, Jing Ouyang, Robert Redd, Scott J. Rodig, Margaret A. Shipp, Mariana Sacchi, Anne Sumbul, Philippe Armand, Stephen M. Ansell - Journal of Clinical Oncology 2019 cited by 256